Kusano E, Asano Y, Takeda K, Matsumoto Y, Ebihara A, Hosoda S
Arzneimittelforschung. 1982;32(12):1575-80.
The hypotensive effect of 4-(2'-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxydimethylester (nifedipine, Adalat) was studied in 15 hypertensive patients with chronic renal failure. The decrease of blood pressure lasted for approximately 3 h and maximum decrement was achieved in 1 h after oral administration of nifedipine (10 mg). Hypotensive action of the drug was associated with a constant decrease in total peripheral resistance and an increase in cardiac output, plasma renin activity (PRA), and plasma norepinephrine (noradrenaline). Initial PRA was apparently the major determinant of the rise in PRA since a close correlation was present between the initial value and the increase induced by nifedipine (r = 0.93, p less than 0.05). Marked reduction of blood pressure without noticeable side effects was observed in two cases who had not responded to previous antihypertensive treatment. These data suggest that nifedipine exerts its hypotensive action through peripheral vasodilation and may be an effective drug for treatment of hypertension during chronic renal failure.
在15例慢性肾功能衰竭的高血压患者中研究了4-(2'-硝基苯基)-2,6-二甲基-1,4-二氢吡啶-3,5-二羧酸二甲酯(硝苯地平,心痛定)的降压作用。口服硝苯地平(10毫克)后,血压下降持续约3小时,1小时后达到最大降幅。该药物的降压作用与总外周阻力持续降低以及心输出量、血浆肾素活性(PRA)和血浆去甲肾上腺素(去甲肾上腺素)增加有关。初始PRA显然是PRA升高的主要决定因素,因为初始值与硝苯地平诱导的升高之间存在密切相关性(r = 0.93,p < 0.05)。在之前的抗高血压治疗无效的2例患者中观察到血压显著降低且无明显副作用。这些数据表明硝苯地平通过外周血管舒张发挥其降压作用,可能是治疗慢性肾功能衰竭期间高血压的有效药物。